Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

Abroad (travel likely)RecruitingPHASE2

Conditions

Urothelial Carcinoma · Advanced Urothelial Carcinoma · Urothelial Carcinoma Recurrent

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
Study leads
  • Yanxia Shi, Doctor

    Principal Investigator

    Sun Yat-Sen University Cancer Center